This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
|Articles|November 1, 2012
Employers, Unions Jointly Demand Health Care Price Transparency
Advertisement
Employees who feel completely mystified by the prices they’re charged for medical procedures might be surprised to know their employers feel the same way. On Thursday, a consortium of major companies and labor unions, including GE, Wal-Mart, Boeing and the AFL-CIO
Consumers “have the right to know the price and quality of their health care choices,” the consortium said in a statement — especially as health care costs continue to rise and high-deductible health care plans become more common.
Read the full story:
Source: Kaiser Health News
Advertisement
Related to this article
With the midterms behind them, health system leaders say coverage losses, thin margins, and payer fights are coming no matter who controls Congress.
New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.
First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.
Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.
A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5